The Infectious Vaccines Partnering Terms and Agreements report provides a detailed understanding and analysis of how and why companies enter infectious vaccines partnering deals.

The Vaccine Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the vaccine partnering deals and agreements entered into by the worlds leading healthcare companies

The Cancer Vaccine Partnering Agreements report provides an understanding and access to the cancer vaccine partnering deals and agreements entered into by the worlds leading healthcare companies

The Diagnostic Imaging Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the diagnostic imaging partnering agreements entered into by the worlds leading healthcare companies.

Industry trends suggest that vaccine research and development is an increasingly active component of healthcare business development. In recent years there has been a significant increase in vaccine partnering and M&A activity.

Recent trends analysis suggests that research in personalized medicine and vaccine development for disease treatment has increased partnering and collaboration in this arena. 

A vaccine is a biological preparation that improves immunity to a particular disease.

Industry trends suggest that infectious vaccines research and development is an increasingly active component of healthcare business development. The last decade has witnessed a significant number of infectious vaccines partnering and M&A activity

A cancer vaccine is a vaccine that treats existing cancer or prevents the development…

A vaccine is a biological preparation that improves immunity to a particular disease

Drug maker Ranbaxy Laboratories is likely to sell off Biovel, a Bangalore-based vaccine manufacturing company which it had acquired in 2010.

CSL is a large speciality biopharmaceutical company developing and manufacturing plasma products and vaccines to treat and protect patients worldwide.

In dealtalk, Novartis plans to exit an eight-year-old vaccines joint venture with India’s Panacea Biotec and intends to go it alone.

In the pharma rumor mill: GlaxoSmithKline may be suffering through a corruption scandal in China, but that hasn’t interfered with its plans to team up with a Chinese company on vaccines.

Ichor Medical Systems has entered into a product development collaboration and worldwide license agreement with Janssen Pharmaceuticals

VBI Vaccines has entered into a research collaboration with Sanofi Pasteur to apply VBI’s LPV (Lipid Particle Vaccine) formulation technology

The International AIDS Vaccine Initiative has received a grant of US$350,000 from GSK to support implementation of the Human Vaccines Project,

Immunomic Therapeutics and Astellas Pharma have entered into an exclusive license agreement for Japan to develop and commercialize JRC2-LAMP-vax

Moderna Therapeutics announced a license and collaboration agreement with Merck for the discovery and development of vaccines and passive immunity treatments against viral diseases

Pfizer has acquired a controlling interest in Redvax

Vaccinex has entered into a research collaboration with Janssen Research & Developmentfor the creation of novel anti-cancer agents

Merck and NewLink Genetics have entered into an exclusive worldwide license agreement to research, develop, manufacture, and distribute NewLink’s investigational rVSV-EBOV (Ebola) vaccine candidate

Novartis announced has entered an agreement that CSL has acquired its influenza vaccine business in a $275 million deal that will require regulatory approval before it closes by the end of the second half of 2015.

GlaxoSmithKline and Johnson & Johnson will become pharma partnering for increasing production of an Ebola vaccine, with an aim to produce at least 1 million doses next year.